Comparative Pharmacology
Head-to-head clinical analysis: BRIVIACT versus TIAGABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVIACT versus TIAGABINE HYDROCHLORIDE.
BRIVIACT vs TIAGABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days.
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination.
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Category C
Category A/B
Anticonvulsant
Anticonvulsant